Drugs / flavocoxid
flavocoxid
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01335295 | Mar 2011 → Dec 2013 | Duchenne muscular dystrophy | University of Messina | Completed | No outcome recorded |
| Phase 1 | NCT00294125 | Feb 2006 → Nov 2007 | osteoarthritis | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00790985 | Jan → Aug 2008 | osteoarthritis, knee | Primus Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | flavocoxid | “Dietary Supplement: flavocoxid” NCT00790985 ↗ |
| Known as | Baicalin-catechin mixture | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095276 ↗ |
| Known as | Flexilerx | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095276 ↗ |
| Known as | Limbrel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095276 ↗ |
| Action | Inhibit | “Flavocoxid, a botanical extract derived from two plants, Scutellaria baicalensis and Acacia catechu, has been shown to inhibit COX-1 and -2 as well as 5-LO.” NCT00294125 ↗ |
| Modality | Other / unclassified | “flavonoid mixture” NCT00790985 ↗ |
| Route | Oral | “daily oral dose of 500 or 1000 mg/die” NCT01335295 ↗ |